Thermo Fisher's (TMO) share price surge is disappointing for investors wishing to acquire grossly undervalued shares in this high quality company. In recent TMO posts with the most recent being that on July 7, 2025, I suggest that negative investor sentiment presents an investment opportunity. Following the July 23, 2025 Q2 and YTD2025 earnings release, [...]
I last reviewed Intuitive Surgical (ISRG) in this June 10, 2025 post at which time the most currently available financial information was for Q1 2025. With the recent release of Q2 and YTD2025 results, I revisit this existing holding. Business Overview The Overview section commencing on page 26 of 58 in the Q2 2025 Form [...]
I last reviewed Danaher Corporation (DHR) in this April 25, 2025 post at which time the most current financial information was for Q1 2025. On July 21, 2025, I acquired an additional 100 shares @ $188.30 in a 'Core' account in the FFJ Portfolio bringing my exposure to 901 shares. As I finalize this post [...]
I last reviewed Genuine Parts Company (GPC) at which time I recommended that its status as a Dividend King not influence investment decisions. Fixating on dividend metrics is a fundamentally flawed way of investing. The focus should be on a company's total potential shareholder return. On July 24, 2017, I initiated a 300 share GPC [...]
At the time of my prior Cintas post (CTAS), the most currently available financial information was for Q3 and YTD2025. Fast forward and we now have Q4 and FY2025 results and FY2026 outlook thus prompting me to revisit this existing holding. Business Overview Part 1 Item 1 in the FY2024 Form 10-K and the [...]
At the time of my April 25, 2025 Thermo Fisher (TMO) – Headwinds Present A Buying Opportunity post, it had just released its Q1 2025 results and FY2025 guidance. In that post, I disclosed the purchase of: a few TMO shares @ ~$431.03/share in a 'Core' account in the FFJ Portfolio on April 17, 2025; [...]
Rollins (ROL) may not appeal to some investors because the nature of its business is not 'sexy'. Sometimes, however, 'ho hum' businesses can offer investors the potential for very reasonable long-term total shareholder returns. Through its family of brands, ROL provides pest control, termite services and wildlife removal to residential and commercial customers. Looking at [...]
Following the release of Accenture's (ACN) Q3 and YTD2025 results on June 20, 2025, the share price plunged to ~$284 from the prior day's ~$306.50 closing share price. This prompted me to look at its results and outlook. Based on my analysis, I initiated a 200 share position @ ~$284.58 in one of the 'Core' [...]
Copart's valuation improves despite no fundamental change in the company's long term outlook. I have, therefore, acquired an additional 200 shares @ ~$48.12 in a 'Core' account in the FFJ Portfolio on June 18. This is a brief post because I covered CPRT as recently as May 28, 2025 where I disclose the purchase of [...]
Intuitive Surgical (ISRG) is redefining the future of surgery with innovation. Its da Vinci platform ranks as being one of the most disruptive technologies in medtech history thus leading to the company's remarkable success in rewarding long-term shareholders. I last reviewed ISRG in this January 25, 2025 post at which time shares were trading at [...]